OKUR · OnKure Therapeutics, Inc.
$3.95
+0.00 (+0.00%)
At close · Jul 29
Going-concern doubt
— cleared May 5, 2026
The latest filing states the doubt was alleviated.
“As of December 31, 2025, the Company had determined that substantial doubt about the Company's ability to continue as a going concern for a period of at least 12 months from the date of the issuance of those financial statements did exist. However, following completion of the 2026 Private Placement (see Note 9), management believes the Company's cash and cash equivalents will be sufficient to fund its current operating plan for at least the next 12 months from the date of issuance of these consolidated financial statements and as such substantial doubt has been alleviated.”View the 10-Q filed May 5, 2026
Market Cap
$159.56M
Shares
40.40M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.95
Open$4.00
Day$3.83–4.09
52W$1.91–5.38
Avg vol 30d360K
Short int1.2M · 2.9% float · 5.8d
Short vol48%
Last earningsAug 12, 2025
DataApr 2021–Jul 2026
Filing10-Q · May 5
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 5, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 20.7 · elevated
Equity put/call 0.61
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+11%
above
Price vs 50-day avg
−6%
below
RSI (14)
40
neutral
MACD trend
Negative
52-week position
59%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−13%
trailing
6-month return
+65%
trailing
YTD return
+36%
this year
Relative strength
+58%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
5 of 51 funds reported for Jun 30 · net +40.2K sh shares · +4 new
Insider flow
Distributing
Net -$1.7K over 90 days · 100% sells
Short interest
Rising
2.93% of float · ▲ +34.5% MoM · 5.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
51 holders — mid 1-yr range
Squeeze score
62
elevated · 0–100
Fundamentals
EPS growth
+71%
Y/Y
Free cash flow
$-51.9M
Balance sheet
$59.1M
net cash
Quant / Vol
risk profile
Volatility
74%
annualized · 1-yr
Max drawdown
−42%
past year
ATR
8.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+11%
Bullish
Price vs 50-day avg
−6%
Bearish
RSI (14)
40
Neutral
MACD trend
Negative
Bearish
52-week position
59%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $4 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
5 of 51 funds reported for Jun 30 · net +40.2K sh shares · +4 new
Insider flow
Distributing
Net -$1.7K over 90 days · 100% sells
Short interest
Rising
2.93% of float · ▲ +34.5% MoM · 5.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
51 holders — mid 1-yr range
Price context
position in its 52-week range
52-wk low $2
Now $4 · 59%
52-wk high $5
vs 200-day avg +11%
vs 50-day avg -6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Patients dosed across both Parts A and B of PIKture-01 | 71 | as of the date of the release | — |
| Patients dosed in fulvestrant combination arm (Part B) | 33 | as of the date of the release | — |
| Patients dosed in monotherapy arm (Part A) | 38 | as of the date of the release | — |
| Patients dosed in Part E (OKI-219 + fulvestrant + ribociclib triplet) | 17 | as of the date of the release | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OKUR
this stock
OnKure Therapeutics, Inc.
|
$159.56M | +36.2% | — | — | 2.9% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +7.7% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +6.6% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +4.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OKUR | -8.6% | -13.4% | +64.6% | -13.4% | +36.2% |
| SPY | -2.4% | -2.3% | +6.3% | -2.3% | +7.0% |
| vs SPY | -6.2% | -11.1% | +58.3% | -11.1% | +29.2% |